Your Local Pharmacy Just Loaded Up On This Drug...

CVS starts selling cannabis products...

Written by Jimmy Mengel
Posted March 28, 2019

The largest pharmacy chain in the country is clearing shelf space for the hottest new drug out there: CBD.

Starting now, you’ll be able to purchase over-the-counter CBD products at more than 800 CVS stores all around the country. The products being sold at CVS are a mixture of creams, lotions, and vape pens.

By now, you probably know that CBD — or cannabidiol — is the non-psychoactive compound in the cannabis plant. It doesn't get you high, which is why it is now federally legal, opening the door to drug stores everywhere.

In an official statement, CVS called it “an alternative source of relief” for common conditions ranging from anxiety to insomnia and pain.

Imagine having an affordable, safe, and non-addictive alternative to Xanax, Ambien, and Oxycontin. Wouldn't you give that a try if it was sitting on the shelf on the way to fill your prescription?

I think millions will — and CVS is betting on it.

This news comes on the heels of Martha Stewart teaming with Canopy Growth (NYSE: CGC) to sell CBD products in Walmart. Once sales figures start rolling in, I wouldn’t be at all surprised to see CBD products in Target or at gas stations and shopping mall kiosks — basically everywhere you go.

In fact, cannabis in general is the fastest-growing consumer segment in the United States.

Many companies — and their investors — will be handsomely rewarded for getting in before these big events take place. In fact, one company already has been...

To get its supply, CVS teamed up with Curaleaf Holdings (OTCPK: CURLF) to distribute its line of CBD products.

It produces disposable vape pens, tinctures, softgel capsules, patches, topical lotion, and even pet treats designed to, as it puts it, “Relax, Relieve and Uplift.”

I can easily see the appeal of its product line, beckoning from the shelf of my local Maryland CVS:

It also operates the largest national brand of retail dispensaries in the U.S. across 13 states. In Florida, it's even opened up the first cannabis drive-through.

Curaleaf stock immediately jumped 51% on the news at one point. I have to believe it will only keep going as it gets name recognition from this deal, and even further as it starts moving product in hundreds of stores around the country.

Folks in the U.S. spent over $360 billion in retail pharmacies last year, so that’s a mighty nice market to step into. But I've been looking into a far bigger market where CBD will begin to make news.

CBD can be — and is being — used for all types of health problems, like I mentioned above. While consumer product companies like Curaleaf should continue to do well, biotech companies have much higher ceilings.

One of the reasons is that, unlike consumer products, they can patent their life-saving drugs and become the only bottle on the shelf.

The one company I have my eyes on is currently working through Phase 1 clinical trials for a CBD heart disease treatment, with plans for Phase 2 later this year.

Just one of its drugs could blow over-the-counter consumer profits out of the water.

Heart disease is one of the deadliest and most costly health problems to ever exist.

The American Heart Association released a report predicting that costs related to heart disease are expected to double from $555 billion in 2016 to a whopping $1.1 trillion in 2035.

Despite the huge amount of money being spent on treatment, innovation on new treatments has been tragically slow…

But CBD could be an answer to this problem.

From one study:

The root cause of heart failure is inflammation in the tissues of the heart. The muscles swell up, stiffen, and fail to pump enough oxygen-rich blood to support your body.

If you can reverse the inflammation, you can heal the heart.

That’s what the science shows CBD can do.

It flushes out inflammation in diabetic cardiomyopathy. It prevents tissues from stiffening up in autoimmune myocarditis. It dramatically reduces cardiac ischemia.

The tiny company I've discovered has developed a breakthrough treatment with the University of Alberta over the past eight years at a cost of more than $3.5 million in R&D expenditures. The scientists who invented it are part of an in-house team of world-leading cardiologists, immunologists, oncologists, and recognized authorities on drug delivery.

It has also teamed up with the Cleveland Clinic, which was rated the #1 U.S. hospital for adult cardiology & heart surgery by U.S. News and World Report.

These are big players, and their trials could be a game-changer for CBD medications and cannabis investors.

I urge you to learn more about this groundbreaking treatment here.


Jimmy Mengel

follow basic @mengeled on Twitter

Jimmy is a managing editor for Outsider Club and the investment director of the personal finance advisory, The Crow's Nest, and cannabis stocks advisory, The Marijuana Manifesto. For more on Jimmy, check out his editor's page.

*Follow Outsider Club on Facebook and Twitter.

Heal Your Ailing Portfolio Body